Type 1 interferons as a potential treatment against COVID-19.
Identifieur interne : 001763 ( Main/Corpus ); précédent : 001762; suivant : 001764Type 1 interferons as a potential treatment against COVID-19.
Auteurs : Erwan Sallard ; François-Xavier Lescure ; Yazdan Yazdanpanah ; France Mentre ; Nathan Peiffer-SmadjaSource :
- Antiviral research [ 1872-9096 ] ; 2020.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents, Interferon Type I.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Humans, Pandemics.
Abstract
Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.
DOI: 10.1016/j.antiviral.2020.104791
PubMed: 32275914
PubMed Central: PMC7138382
Links to Exploration step
pubmed:32275914Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Type 1 interferons as a potential treatment against COVID-19.</title>
<author><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name>
<affiliation><nlm:affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32275914</idno>
<idno type="pmid">32275914</idno>
<idno type="doi">10.1016/j.antiviral.2020.104791</idno>
<idno type="pmc">PMC7138382</idno>
<idno type="wicri:Area/Main/Corpus">001763</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001763</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Type 1 interferons as a potential treatment against COVID-19.</title>
<author><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name>
<affiliation><nlm:affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name>
<affiliation><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (isolation & purification)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Humans (MeSH)</term>
<term>Interferon Type I (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (virology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon Type I</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Pandemics</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32275914</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>178</Volume>
<PubDate><Year>2020</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Type 1 interferons as a potential treatment against COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>104791</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0166-3542(20)30205-9</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2020.104791</ELocationID>
<Abstract><AbstractText>Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sallard</LastName>
<ForeName>Erwan</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lescure</LastName>
<ForeName>François-Xavier</ForeName>
<Initials>FX</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yazdanpanah</LastName>
<ForeName>Yazdan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mentre</LastName>
<ForeName>France</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peiffer-Smadja</LastName>
<ForeName>Nathan</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Interferon</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
</KeywordList>
<CoiStatement>Declaration of competing interest None.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32275914</ArticleId>
<ArticleId IdType="pii">S0166-3542(20)30205-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2020.104791</ArticleId>
<ArticleId IdType="pmc">PMC7138382</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001763 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001763 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidFranceV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32275914 |texte= Type 1 interferons as a potential treatment against COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32275914" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidFranceV1
This area was generated with Dilib version V0.6.37. |